AbbVie (ABBV) has been demonstrating a strong momentum in its performance with various successful updates. The company declared a
quarterly dividend of $1.55, yielding 3.6%. FDA has given nod to
Skyrizi for
ulcerative colitis which boosts the company's portfolio. The company's stock trade was slightly down by 0.5%, but reasons underlining it as a solid purchase were highlighted. BTC Capital Management and other investor groups have reportedly acquired substantial shares of AbbVie. New positions were held by
Roxanne S. Austin as she joined the board. The company's status as a
dividend stock was also emphasized. AbbVie’s
ovarian cancer therapy met the study goal, expanding interests in this promising stock. The firm started a late-stage study on
multiple myeloma drug and the first subject for Phase III trial got treated. Its partnership with
OSE Immunotherapeutics for a novel
monoclonal antibody development was also marked. AbbVie's successful acquisition of
Landos Biopharma is expected to strengthen its portfolio in inflammatory and autoimmune diseases.
Q1 earnings topped the estimates despite revenue challenges.
Abbvie ABBV News Analytics from Thu, 25 Jan 2024 08:00:00 GMT to Sun, 23 Jun 2024 11:36:49 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -1
